References
- Migliori GB, Wu SJ, Matteelli A, Zenner D, Goletti D, Ahmedov S,
Al-Abri S, Allen DM, Balcells ME, Garcia-Basteiro AL, Cambau E.
Clinical standards for the diagnosis, treatment and prevention of TB
infection. The International Journal of Tuberculosis and Lung Disease.
2022 Mar 1;26(3):190-205.
- World Health Organization, Stop TB Initiative (World Health
Organization). Treatment of tuberculosis: guidelines. World Health
Organization; 2010.
- Jeong YJ, Lee KS. Pulmonary tuberculosis: up-to-date imaging and
management. AJR Am J Roentgenol. 2008 Sep 1;191(3):834-44.
- Kim HY, Cho JG, Akkerman OW, Padanilam X, Seaworth B, Alffenaar JW.
Anti-Tuberculosis Drugs and Adverse Events. Essential Tuberculosis.
2021:121-9.
- Mockenhaupt M. Epidemiology of cutaneous adverse drug reactions.
Adverse Cutaneous Drug Eruptions. 2012;97:1-7.
- García RM, Molina SC. Drug-induced hyperpigmentation: review and case
series. The Journal of the American Board of Family Medicine. 2019 Jul
1;32(4):628-38.
- Lode H, Rubinstein E. Adverse effects. Quinolone antimicrobial agents.
2003 Aug 12:405-19.
- Baggio D, Ananda-Rajah MR. Fluoroquinolone antibiotics and adverse
events. Australian prescriber. 2021 Oct;44(5):161.
- Lorente M, Ballano A, Juanes A, Pastor MA, Cuevas J. Blue-Gray
Pigmentation in Trunk and Extremities in a 71-Year-Old Man.JAMA Dermatol. 2013;149(9):1111–1112.
- Redondo RG, Molero VM, Fuentes AM, de Eusebio Murillo E. Le
vofloxacin-Induced Hyperpi gmentation.
- Connors TM, Restrepo A, Dao Jr H. Brown-gray hyperpigmentation in a
photosensitive distribution after levofloxacin exposure. Dermatology
Online Journal. 2018;24(7)
- Le Cleach L, Chosidow O, Peytavin G, Berry JP, Boisnic S, Le
Charpentier Y, Herson S, Frances C. Blue-black pigmentation of the
legs associated with pefloxacin therapy. Archives of dermatology. 1995
Jul 1;131(7):856-7.
- Llau ME, Viraben R, Montastruc JL. Drug-induced alopecia: review of
the literature. Therapie. 1995 Mar 1;50(2):145-50.
- World Health Organization. WHO operational handbook on tuberculosis.
module 4: Treatment-drug-resistant tuberculosis treatment, 2022
update. World Health Organization; 2022 Dec 15.